241 related articles for article (PubMed ID: 36866734)
61. Promises and challenges of biologics for severe asthma.
Tan R; Liew MF; Lim HF; Leung BP; Wong WSF
Biochem Pharmacol; 2020 Sep; 179():114012. PubMed ID: 32389637
[TBL] [Abstract][Full Text] [Related]
62. Urine eosinophil-derived neurotoxin: A potential marker of activity in select eosinophilic disorders.
Makiya MA; Khoury P; Kuang FL; Mata AD; Mahmood S; Bowman A; Espinoza D; Kovacs N; Brown T; Holland N; Wetzler L; Ware JM; Dyer AM; Akuthota P; Bochner BS; Chinchilli VM; Gleich GJ; Langford C; Merkel PA; Specks U; Weller PF; Wechsler ME; Prussin C; Fay MP; Klion AD
Allergy; 2023 Jan; 78(1):258-269. PubMed ID: 35971862
[TBL] [Abstract][Full Text] [Related]
63. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
McBrien CN; Menzies-Gow A
Drugs Today (Barc); 2018 Feb; 54(2):93-101. PubMed ID: 29637936
[TBL] [Abstract][Full Text] [Related]
64. New Targeted Therapies for Uncontrolled Asthma.
Corren J
J Allergy Clin Immunol Pract; 2019; 7(5):1394-1403. PubMed ID: 31076057
[TBL] [Abstract][Full Text] [Related]
65. Strategies for choosing a biologic for your patient with allergy or asthma.
Saco T; Ugalde IC; Cardet JC; Casale TB
Ann Allergy Asthma Immunol; 2021 Dec; 127(6):627-637. PubMed ID: 34642091
[TBL] [Abstract][Full Text] [Related]
66. Cost-Effectiveness of Biologics for Allergic Diseases.
Wu AC; Fuhlbrigge AL; Robayo MA; Shaker M
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1107-1117.e2. PubMed ID: 33069886
[TBL] [Abstract][Full Text] [Related]
67. Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment.
Latorre M; Bacci E; Seccia V; Bartoli ML; Cardini C; Cianchetti S; Cristofani L; Di Franco A; Miccoli M; Puxeddu I; Celi A; Paggiaro P
Ther Adv Respir Dis; 2020; 14():1753466620965151. PubMed ID: 33263506
[TBL] [Abstract][Full Text] [Related]
68. Eosinophilic granulomatosis with polyangitis: A new target for biologicals.
Bayrak Durmaz MS; Çelebi Sözener Z; Bavbek S
Tuberk Toraks; 2022 Mar; 70(1):93-101. PubMed ID: 35362309
[TBL] [Abstract][Full Text] [Related]
69. The emerging roles of eosinophils: Implications for the targeted treatment of eosinophilic-associated inflammatory conditions.
Lombardi C; Berti A; Cottini M
Curr Res Immunol; 2022; 3():42-53. PubMed ID: 35496822
[TBL] [Abstract][Full Text] [Related]
70. [Biologicals in the Treatment of Bronchial Asthma].
Haasler I; Taube C
Pneumologie; 2017 Oct; 71(10):684-698. PubMed ID: 29017221
[TBL] [Abstract][Full Text] [Related]
71. Biologics for the Treatment of Allergic Rhinitis, Chronic Rhinosinusitis, and Nasal Polyposis.
Eschenbacher W; Straesser M; Knoeddler A; Li RC; Borish L
Immunol Allergy Clin North Am; 2020 Nov; 40(4):539-547. PubMed ID: 33012318
[TBL] [Abstract][Full Text] [Related]
72. Biologics for Eosinophilic Granulomatosis With Polyangiitis-One Size Does Not Fit All: Comment on the Article by Canzian et al.
Caminati M; Giollo A; Senna G; Lunardi C
Arthritis Rheumatol; 2021 Jul; 73(7):1346-1347. PubMed ID: 33605091
[No Abstract] [Full Text] [Related]
73. Novel targets of omalizumab in asthma.
Sattler C; Garcia G; Humbert M
Curr Opin Pulm Med; 2017 Jan; 23(1):56-61. PubMed ID: 27798419
[TBL] [Abstract][Full Text] [Related]
74. Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma.
Roufosse F
Front Med (Lausanne); 2018; 5():49. PubMed ID: 29682504
[TBL] [Abstract][Full Text] [Related]
75. Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases.
Jackson K; Bahna SL
Expert Rev Clin Immunol; 2020 Mar; 16(3):311-319. PubMed ID: 31994421
[No Abstract] [Full Text] [Related]
76. Sequential rituximab and omalizumab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
Aguirre-Valencia D; Posso-Osorio I; Bravo JC; Bonilla-Abadía F; Tobón GJ; Cañas CA
Clin Rheumatol; 2017 Sep; 36(9):2159-2162. PubMed ID: 28762062
[TBL] [Abstract][Full Text] [Related]
77. Eosinophilic granulomatosis with polyangiitis with heterozygous familial hypercholesterolemia: A tricky therapeutic approach with omalizumab and evolocumab.
Sbrana F; Dal Pino B; Ferro F; Corciulo C; Puxeddu I; Baldini C
Nutr Metab Cardiovasc Dis; 2023 Feb; 33(2):461-464. PubMed ID: 36642612
[No Abstract] [Full Text] [Related]
78. Neutrophil infiltrates and eosinophil aggregates in chronic rhinosinusitis with nasal polyps and EGPA.
Contro G; Brescia G; Alessandrini L; Barion U; Padoan R; Frigo AC; Schiavon F; Marioni G
Clin Rheumatol; 2021 May; 40(5):1949-1957. PubMed ID: 33094393
[TBL] [Abstract][Full Text] [Related]
79. The use of biologics in food allergy.
Fiocchi A; Vickery BP; Wood RA
Clin Exp Allergy; 2021 Aug; 51(8):1006-1018. PubMed ID: 33966304
[TBL] [Abstract][Full Text] [Related]
80. Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions.
Harish A; Schwartz SA
Clin Rev Allergy Immunol; 2020 Oct; 59(2):231-247. PubMed ID: 31919743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
